Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autonomix MedicalAMIX -12.48%15 Equity-to-Asset is 0.78 as of Mar. 2026, which is 1% below its 10-year median of 0.79. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Autonomix Medical ranks better than 71.93% on this metric.
The historical rank and industry rank for Autonomix Medical's Equity-to-Asset or its related term are showing as below:
AMIX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.75 Med: 0.79 Max: 0.83
Current: 0.78
During the past 4 years, the highest Equity to Asset Ratio of Autonomix Medical was 0.83. The lowest was 0.75. And the median was 0.79.
AMIX's Equity-to-Asset is ranked better than 71.93% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs AMIX: 0.78
Autonomix Medical (NAS:AMIX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Autonomix Medical Equity-to-Asset Related Terms
Autonomix Medical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Autonomix Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMIX vs BJDX, LUDG, ALURD: Equity-to-Asset Comparison
For the Medical Devices subindustry, Autonomix Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autonomix Medical Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Autonomix Medical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Autonomix Medical's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autonomix Medical (AMIX) has a Equity-to-Asset of 0.78 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Autonomix Medical and its competitors. This is near median its historical median of 0.79. Over the past decade, Autonomix Medical's Equity-to-Asset has ranged from 0.75 to 0.83. According to the industry distribution chart, Autonomix Medical ranks #240 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 28.1%.
Is Autonomix Medical's Equity-to-Asset too high?
Autonomix Medical's current Equity-to-Asset of 0.78 is near median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 0.83. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Autonomix Medical's value of 0.78 is 20% above this industry median. Based on the distribution chart, Autonomix Medical ranks #240 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's Equity-to-Asset compare to BJDX and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Autonomix Medical ranks #240 out of 855 companies for Equity-to-Asset. This puts Autonomix Medical in the upper half of its industry. The industry median Equity-to-Asset is 0.65. Autonomix Medical's value of 0.78 is 20% above this benchmark. Historically, Autonomix Medical's own Equity-to-Asset has ranged from 0.75 to 0.83 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 0.65, Autonomix Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autonomix Medical's current Equity-to-Asset of 0.78 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Autonomix Medical and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autonomix Medical's current Equity-to-Asset is 0.78, which is near median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current Equity-to-Asset of 0.78. The current Equity-to-Asset is 0.78, which is near median its 10-year median of 0.79 and 20% above the Medical Devices & Instruments industry median of 0.65. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current Equity-to-Asset is 0.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score
Get the complete analysis for AMIX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMIX has been successfully added to your 
